Curebound Names Robin Toft as Chief Executive Officer

Founding CEO Anne Marbarger to join board of directors and serve as advisor

Curebound, a philanthropic organization that fundraises for and invests in innovative cancer research, today announced that Robin Toft has been appointed chief executive officer, effective January 1. Toft succeeds founding CEO Anne Marbarger, who will join the Curebound Board of Directors and serve as an advisor to Toft and the leadership team, ensuring continuity as the organization enters its next decade of impact.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251202319824/en/

Robin Toft has been appointed chief executive officer of Curebound, effective January 1, 2026. Toft brings a wealth of experience to her new role, with a strong track record of scaling entrepreneurial companies and nonprofit organizations. An established business leader, she has built a reputation for accelerating life-saving technologies to market for healthcare and life science organizations by assembling leadership teams that drive innovation and profitability. Before joining Curebound’s Board of Directors, Toft built and sold an executive search firm focused on improving cancer care. A grateful colon cancer survivor, Toft is deeply committed to driving research innovation and investing in cancer studies that support Curebound’s vision to find cures in our lifetime.

Toft brings a wealth of experience to her new role, with a strong track record of scaling entrepreneurial companies and nonprofit organizations. An established business leader, she has built a reputation for accelerating life-saving technologies to market for healthcare and life science organizations by assembling leadership teams that drive innovation and profitability. Before joining Curebound’s Board of Directors, Toft built and sold an executive search firm focused on improving cancer care.

Toft has extensive board leadership experience and currently serves on the Board of Directors for the American Cancer Society’s San Diego Chapter and the La Jolla Institute of Immunology. On the Curebound Board of Directors, she spent two years as secretary, established and chaired the nominating governance committee, and now leads the advancement committee. A grateful colon cancer survivor, Toft is deeply committed to driving research innovation and investing in cancer studies that support Curebound’s vision to find cures in our lifetime.

“I can’t imagine a more inspirational embodiment of Curebound’s mission and culture than Robin. Her personal and professional support of innovative cancer research and Curebound’s vision has been extraordinary,” said Curebound Board Chair and Co-Founder Bill Koman. “As founding CEO, Anne has created a strong foundation for Curebound and we are delighted she will serve on the Board as the CEO role transitions into Robin’s capable hands and we continue to scale the organization.”

Anne Marbarger devoted the past decade to advancing innovative cancer research at Curebound’s predecessor organization, Padres Pedal the Cause, followed by five years as the founding CEO of Curebound. She helped conceptualize and oversee the merger of Padres Pedal the Cause and the Immunotherapy Foundation, and built enduring partnerships with leading cancer research institutions and corporate supporters to help create what is now Curebound—a powerhouse philanthropic organization.

Toft says she is deeply dedicated to Curebound’s mission and focused on driving continued growth in fundraising, partnerships, and patient impact.

“I look forward to embarking on this new journey with Curebound and continuing the legacy that our CEO Anne Marbarger and co-founders Bill and Amy Koman and Fernanda and Ralph Whitworth have created,” Toft said. “Together with our dedicated team, supporters and partners, Curebound will continue to fund promising early-stage studies that can change the future of cancer treatment. With federal funding cuts and dozens of vital studies at risk, we must continue to boldly support high-risk, high-reward research led by the brightest scientific minds to bring the next generation of life-saving discoveries to patients.”

For more information about Curebound, visit www.curebound.org.

To learn more about becoming a donor, visit www.curebound.org/get-involved.

About Curebound

Curebound is a philanthropic organization that fundraises and invests in cancer research with the power to save lives. Through collaborative grants, corporate partnerships, and strategic investments, Curebound’s aim is to significantly accelerate better prevention, detection, and treatments for cancer. Headquartered in the major U.S. biotech hub of San Diego, amid 3,000+ life sciences companies, leading health systems, and world-class research institutions, Curebound partners with these organizations to forge interdisciplinary collaboration, foster knowledge sharing, and fund pioneering cancer research. So far, Curebound has funded $43 million in cancer research, awarding 142 study grants for 23 types of pediatric and adult cancers with one vision: cures in our lifetime. Join us - www.curebound.org.

View source version on businesswire.com: https://www.businesswire.com/news/home/20251202319824/en/

“I can’t imagine a more inspirational embodiment of Curebound’s mission than Robin. Her personal and professional support of innovative cancer research and Curebound’s vision has been extraordinary,” said Curebound Board Chair and Co-Founder Bill Koman.